Loading stock research

First Trust SMID Growth Strength ETF

FSGS

Financial ServicesNASDAQUS

Sign in to save

$30.845

-$0.33 (-1.06%)

Overview Financials Analysis Valuation Thesis Ownership Compare AI Report News

FSGS News

News and disclosures filtered by period, publisher, and event group.

2 / 2

Filter options

Results

Select a headline to open the full news page in the app.

Jun 4, 2026, 12:00 AMgurufocus.comFSGS

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

Company announcements

HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen

Jun 2, 2026, 8:00 AMgurufocus.comFSGS

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

Company announcements

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f

Loading disclosure news